The effect of antipsychotic-induced extrapyramidal disorders on patient’s compliance with schizophrenia (a clinical case)
https://doi.org/10.20538/1682-0363-2021-4-211-217
Abstract
Extrapyramidal disorders are common adverse events in antipsychotic therapy. However, their diagnosis is difficult due to broad differential diagnosis, and often their specific clinical variant is not recognized, and timely intervention is not performed, which leads to severe patient suffering. This affects the quality of life of patients with schizophrenia and leads to their refusal to receive therapy, which aggravates the course of the disease. The article presents a clinical case of a 33-year-old patient at a psychiatric hospital with schizophrenia combined with such rare severe extrapyramidal disorders as antipsychotic-induced tardive dyskinesia and tardive dystonia.
The diagnosis was carried out in accordance with the criteria of the International Classification of Diseases, Tenth Revision (ICD-10). The intensity of clinical manifestations was assessed using the Positive and Negative Syndrome Scale (PANSS), the Abnormal Involuntary Movement Scale (AIMS), and the Barnes Akathisia Rating Scale (BARS). Compliance was assessed using the Method for Measuring Medication Adherence in Psychiatry. Detailed differential diagnosis of tardive dyskinesia and tardive dystonia with akathisia and Huntington’s disease was presented. Substantiated treatment strategy and positive clinical dynamics with increased compliance were described.
About the Authors
E. G. Rahim
Mental Health Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Russian Federation
4, Aleutskaya Str., Tomsk, 634014
E. G. Kornetova
Mental Health Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences;
Siberian State Medical University (SSMU)
Russian Federation
Russian Federation
4, Aleutskaya Str., Tomsk, 634014
2, Moscow Trakt, Tomsk, 634050
A. A. Goncharova
Mental Health Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Russian Federation
4, Aleutskaya Str., Tomsk, 634014
A. N. Кornetov
Siberian State Medical University (SSMU)
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
A. V. Semke
Mental Health Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Russian Federation
4, Aleutskaya Str., Tomsk, 634014
References
1. Дмитриева Е.Г., Даниленко О.А., Корнетова Е.Г., Семке А.В., Лобачева О.А., Гуткевич Е.В., Каткова М.Н. Комплаенс и его влияние на адаптацию пациентов с шизофренией. Сибирский вестник психиатрии и наркологии. 2014; (3): 18–23.
2. Семке А.В., Федоренко О.Ю., Лобачева О.А., Рахмазова Л.Д., Корнетова Е.Г., Смирнова Л.П., Микилев Ф.Ф., Щигорева Ю.Г. Клинические, эпидемиологические и биологические предпосылки адаптации больных шизофренией как основа персонифицированного подхода к антипсихотической терапии. Сибирский вестник психиатрии и наркологии. 2015; (3): 19–25.
3. Иванов М.В., Костерин Д.Н. Эффективность антипсихотической терапии препаратами пролонгированного действия у больных шизофренией в долгосрочной перспективе. Сибирский вестник психиатрии и наркологии. 2017; (3): 84–91. DOI: 10.26617/1810-3111–2017-3(96)-84-91.
4. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry. 2002; 63 (10): 892– 909. DOI: 10.4088/jcp.v63n1007.
5. Chandra I.S., Kumar K.L., Reddy M.P., Reddy C.M. Attitudes toward medication and reasons for non-compliance in patients with schizophrenia. Indian Journal of Psychological Medicine. 2014; 36 (3): 294–298. DOI: 10.4103/0253-7176.135383.
6. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., Adler L.W., Manschreck T.C., Swartz M., Rosenheck R., Perkins D.O., Walker T.M., Stroup T.S., McEvoy J.P., Lieberman J.A. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006; 31 (9): 2033–2046. DOI: 10.1038/sj.npp.1301072.
7. Phillips E.L. Patient compliance: New light on health delivery systems in medicine and psychotherapy. Hogrefe & Huber Publishers, 1988: 20.
8. Дубровская В.В., Корнетова Е.Г., Семке А.В., Иванова С.А., Аржаник М.Б., Головаха Н.Э. Клиническая динамика и социальная адаптация у пациентов с шизофренией и сопутствующим метаболическим синдромом. Современная терапия психических расстройств. 2019; (2): 17–21.
9. Higashi K., Medic G., Littlewood K.J., Diez T., Granström O., De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology. 2013; 3 (4): 200–218. DOI: 10.1177/2045125312474019.
10. Иванова С.А. Фармакогенетика антипсихотик-индуцированной тардивной дискинезии у больных шизофренией. Психическое здоровье. 2018; 16 (4): 19–21. DOI: 10.25557/2074-014X.2018.04.19-21.
11. Klawans H.L., Tanner C.M., Goetz C.G. Epidemiology and pathophysiology of tardive dyskinesia. Advances in Neurology. 1988; 49: 185–197.
12. Meyer J.M. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectrums. 2016; 21 (S1): 13–24. DOI: 10.1017/S1092852916000730.
13. Rana A.Q., Chaudry Z.M., Blanchet P.J. New and emerging treatments for symptomatic tardive dyskinesia. Drug Design Development & Therapy. 2013; 7 (7): 1329–1340. DOI: 10.2147/DDDT.S32328.
14. Charlson F.J., Ferrari A.J., Santomauro D.F., Diminic S., Stockings E., Scott J.G., McGrath J.J., Whiteford H.A. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study. Schizophrenia Bulletin. 2018; 44 (6): 1195–1203. DOI: 10.1093/schbul/sby058.
15. Browne S., Roe M., Lane A., Gervin M., Morris M., Kinsella A., Larkin C., Callaghan E.O. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica et Neurologica Scandinavica. 1996; 94 (2): 118–124. DOI: 10.1111/j.1600-0447.1996.tb09835.x.
16. Cunningham Owens D.G. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. University of Edinburgh, 2014: 383.
17. Stacy M., Jankovic J. Tardive tremor. Movement Disorders. 1992; 7 (1): 53–57. DOI: 10.1002/mds.870070110.
18. Психиатрия: национальное руководство; под ред. Ю.А. Александровского, Н.Г. Незнанова; 2-е изд., перераб. и доп.. М.: ГЭОТАР-Медиа, 2018: 1008.
19. World Health Organization: The ICD-10 Classification of Mental Disorders – Diagnostic Criteria for Research. Geneva: WHO, 1993.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987; 13 (2): 261–276. DOI: 10.1093/schbul/13.2.261.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington DC: Us Department of Health, Education and Welfare: 1976.
22. Barnes T.R. A rating scale for drug-induced akathisia. The British Journal of Psychiatry. 1989; 154 (5): 672–676. DOI: 10.1192/bjp.154.5.672.
23. Лутова Н.Б., Борцов А.В., Вид В.Д., Вукс А. Метод прогнозирования медикаментозного комплайенса в психиатрии: методические рекомендации. СПб., 2007: 26.
24. Burke R.E., Fahn S., Jankovic J., Marsden C.D., Lang A.E., Gollomp S., Ilson J. Tardive dystonya: Late-onset and persistent dystonya caused by antipsychotic drugs. Neurology. 1982; 32 (12): 1335–1346. DOI: 10.1212/wnl.32.12.1335.
25. Dayalu P., Chou K.L. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opinion on Pharmacotherapy. 2008; 9 (9): 1451–1462. DOI: 10.1517/14656566.9.9.1451.
26. Гончарова А.А., Корнетова Е.Г., Корнетов А.Н., Семке А.В. Существует ли конституционально-морфологическая предиспозиция к акатизии у больных шизофренией, получающих антипсихотическую терапию? Бюллетень сибирской медицины. 2019; 18 (4): 36–43. DOI: 10.20538/1682-0363-2019-4-36-43.
27. Остроумова Т.М., Толмачева В.А., Остроумова О.Д., Парфенов В.А. Лекарственная тардивная дискинезия. Неврология, нейропсихиатрия, психосоматика. 2020; 12 (1): 81–86. DOI: 10.14412/2074-2711-2020-1-81-86.
Review
For citations:
Rahim E.G., Kornetova E.G., Goncharova A.A., Кornetov A.N., Semke A.V. The effect of antipsychotic-induced extrapyramidal disorders on patient’s compliance with schizophrenia (a clinical case). Bulletin of Siberian Medicine. 2021;20(4):211-217. https://doi.org/10.20538/1682-0363-2021-4-211-217
Views:
622
Email this article 